BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36269794)

  • 1. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
    Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
    Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
    Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
    Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
    Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
    J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
    Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
    Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
    J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
    Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
    Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.
    Bitansky G; Avigdor A; Vasilev E; Zlotnick M; Ribakovsky E; Benjamini O; Nagler A; Kedmi M
    Leuk Lymphoma; 2020 Nov; 61(11):2645-2651. PubMed ID: 32643497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.
    Sarkozy C; Huet S; Carlton VE; Fabiani B; Delmer A; Jardin F; Delfau-Larue MH; Hacini M; Ribrag V; Guidez S; Faham M; Salles G
    Oncotarget; 2017 Jan; 8(5):8765-8774. PubMed ID: 28060738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.
    Gao F; Zhang T; Liu H; Li W; Liu X; Qiu L; Li L; Zhou S; Qian Z; Dong S; Zhao S; Wang X; Zhang H
    Ann Hematol; 2022 Nov; 101(11):2383-2392. PubMed ID: 36029326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.
    Hatipoğlu T; Esmeray Sönmez E; Hu X; Yuan H; Danyeli AE; Şeyhanlı A; Önal-Süzek T; Zhang W; Akman B; Olgun A; Özkal S; Alacacıoğlu İ; Özcan MA; You H; Küçük C
    Front Oncol; 2022; 12():870487. PubMed ID: 35795062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 15. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
    Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
    Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
    Yoon SE; Cho J; Kim WS; Kim SJ
    J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
    Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
    Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
    Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
    Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat early-relapsing follicular lymphoma.
    Casulo C; Barr PM
    Blood; 2019 Apr; 133(14):1540-1547. PubMed ID: 30700421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.